

# Patient and Caregiver Satisfaction with BAXJECT III, a Next-Generation Reconstitution System for AHF-rFVIII (ADVATE®)

Michelle Witkop<sup>1</sup>, Jennifer Maahs<sup>2</sup>, Diane Ito<sup>3</sup>, Josh Epstein<sup>3</sup>

<sup>1</sup>Northern Regional Bleeding Disorders Center, Traverse City, MI, USA; <sup>2</sup>Indiana Hemophilia & Thrombosis Center, Indianapolis, IN, USA;

<sup>3</sup>Baxter BioScience, Westlake Village, CA, USA

## Introduction

- BAXJECT III is an all-in-one, next generation reconstitution system Baxter is developing for reconstituting ADVATE.
- BAXJECT II is the current reconstitution system available for ADVATE.
- The primary advancement of BAXJECT III is that its design no longer requires users to cleanse and attach the vials of ADVATE and sterile water to the reconstitution system.
- Elimination of these steps allows faster reconstitution and reduction of potential

touch contamination for BAXJECT III when compared to BAXJECT II, which requires users to cleanse and attach the vials to the system.

- A more convenient reconstitution system may help improve patient adherence to their prescribed regimen.
- To assess satisfaction with and preferences for BAXJECT III, a survey was administered in conjunction with a time and motion study.



## Objectives

- To assess patient and caregiver satisfaction and preferences for BAXJECT III or BAXJECT II.
- To assess the likelihood of increased adherence to a prophylaxis regimen with the availability of BAXJECT III.


## Methods

<b>Sample</b>	<ul style="list-style-type: none"> <li>25 hemophilia adult patients and parents/caregivers of children with hemophilia were invited to participate in a BAXJECT III Time &amp; Motion study.</li> <li>Participants were from New York, Los Angeles, and Chicago</li> </ul>
<b>Survey Administration</b>	<ul style="list-style-type: none"> <li>Upon completion of the time and motion study, participants were asked to complete a survey.</li> </ul>
<b>Survey Description</b>	<ul style="list-style-type: none"> <li>This paper-based survey asked participants to compare satisfaction between reconstitution systems:                             <ul style="list-style-type: none"> <li>BAXJECT II</li> <li>BAXJECT III</li> </ul> </li> <li>The survey also asked about their preferences for reconstitution systems, and the likelihood of increased adherence to a prophylaxis regimen with BAXJECT III.</li> </ul>

## Results

Factor VIII Product Used		N (%)
Adult patient		12 (48%)
Caregiver of pediatric patient		13 (52%)
ADVATE		12 (48%)
Helixate FS		3 (12%)
Kogenate FS		3 (12%)
Plasma-derived FVIII		2 (8%)
Recombinant		1 (4%)
Other/unknown		4 (16%)
Who Infuses		
Patient infuses		14 (56%)
Caregiver infuses		6 (24%)
Not specified		5 (20%)
Current Factor Treatment Regimen		
<b>On-demand</b> (only to control bleed)		2 (9.5%)
<b>Regular Prophylaxis</b> (regular schedule of infusions each week)		18 (85.7%)
<b>Intermittent Prophylaxis</b> to Prevent Bleeds (only before a high risk activity)		1 (4.8%)
Not specified		4 (16%)


### Satisfaction with BAXJECT II and BAXJECT III



- More participants were significantly more satisfied with BAXJECT III compared to BAXJECT II on nearly all attributes assessed, except for size of kit (all  $p < 0.05$ ).
- Of note, patients/caregivers were significantly more satisfied with the portability of BAXJECT III compared to BAXJECT II, despite any concerns about the size of the kit ( $p = 0.0253$ ).


## Results (Continued)

### Preference for BAXJECT II or BAXJECT III Among All Participants



- Overall, 96% of respondents preferred BAXJECT III over BAXJECT II.

### Comfort with BAXJECT III




### Time (minutes) to become comfortable with BAXJECT III\*

	N	Mean	Median	Min-max
Patient/Caregiver	24	3.66	2.0	1-20

\*This question was open-ended and asked respondents to estimate the time in minutes to become comfortable with BAXJECT III

- 22 (88%) of patients/caregivers reported that it was 'very easy' to learn how to use BAXJECT III and felt comfortable with it after a median of 2 minutes.
- Additionally, the mean reconstitution time among patients/caregivers was 30.7 seconds for BAXJECT III, compared to 90.5 seconds for BAXJECT II.

### Adherence Challenges with Current FVIII Regimen Among Patients on Prophylaxis




- Approximately 30% of patients/caregivers indicated being 'somewhat' or 'not adherent' to their current prophylaxis therapy regimen.

### BAXJECT III May Help Improve Adherence

- Nearly 80% indicated that BAXJECT III would help improve their adherence to treatment.

### Would BAXJECT III Help Improve Adherence to Treatment Regimen?



## Study Limitations

- Small sample size may limit generalizability of the results.
- Respondents had limited exposure to the BAXJECT III system; may not have had time to fully experience using the new system.

## Conclusions

- Hemophilia patients and caregivers were highly satisfied with BAXJECT III, preferring it over BAXJECT II.
- Most indicated it was very easy to learn to use BAXJECT III, and reported a median of 2 minutes to become comfortable using the system.
- Additionally, most indicated that it may help improve patient adherence to their treatment regimen.



Presented at the WFH 2014 World Congress in Melbourne, Australia • May 11-15, 2014

If you have any additional questions, please feel free to contact Baxter Bioscience Medical Information at [medinfo@baxter.com](mailto:medinfo@baxter.com).

Conflicts of interest: Diane Ito and Josh Epstein are paid employees of Baxter Healthcare Corporation.

